European Neuropsychopharmacology
Volume 13, Issue 5 , Pages 333-335 , October 2003

CSF taurine level is influenced by plasma cholesterol and the CYP2D6 phenotype

  • Conny Nordin

      Affiliations

    • Division of Psychiatry, Department of Neuroscience and Locomotion, University Hospital, SE-581 85 Linköping, Sweden
    • Corresponding Author InformationCorresponding author. Tel.: +46-13-223-864; fax: +46-13-223-392.
    • ,
  • Marja-Liisa Dahl

      Affiliations

    • Department of Medical Sciences, Clinical Pharmacology, Uppsala University Hospital, SE-751 85, Uppsala, Sweden
    • ,
  • Thomas Eklundh

      Affiliations

    • Department of Clinical Neuroscience, Psychiatric Section at the Karolinska Institute, St Görans Hospital, SE-112 81 Stockholm, Sweden
    • ,
  • Mats Eriksson

      Affiliations

    • Department of Medicine, Centre for Metabolism and Endocrinology at the Karolinska Institute, Huddinge Hospital, SE-141 86 Huddinge, Sweden
    • ,
  • Stefan Sjöberg

      Affiliations

    • Department of Medicine, Centre for Metabolism and Endocrinology at the Karolinska Institute, Huddinge Hospital, SE-141 86 Huddinge, Sweden

Received 29 October 2002 ,Revised 6 February 2003 ,Accepted 6 February 2003.

References 

  1. Dahl M-L. Cytochrome P450 pheno/genotyping in patients receivning antipsychotics: useful aid to prescribing?. Clin. Pharmacokinet. 2002;41:453–470
  2. Engelberg H. Low serum cholesterol and suicide. Lancet. 1992;339:727–729
  3. Eriksson M, Eklundh T, Sjöberg S, Angelin B, Nordin C. Cholesterol lowering and cerebrospinal fluid neurotransmitters: Increased levels of the anxiogenic cholecystokinin-tetrapeptide during simvastatin administration to healthy male volunteers. Biol. Psychiatry. 1996;40:302–304
  4. Fellman JH, Roth ES, Fujita TS. Taurine is not metabolized to isethionate in mammalian tissue. In:  Barbeau A,  Huxtable R editor. Taurine and Neurological Disorders. New York: Raven Press; 1978;p. 19–124
  5. Huxtable RJ. Taurine in the central nervous system and the mammalian actions of taurine. Prog. Neurobiol. 1989;32:471–533
  6. Huxtable RJ. Physiological actions of taurine. Physiol. Rev. 1992;72:101–163
  7. Keep RF, Xiang J. Choroid plexus taurine transport. Brain Res. 1996;715:17–24
  8. Kleinbaum DG, Kupper LL, Muller KE, Nizam A. In: Applied Regression Analysis and Other Multivariable Methods. Pacific Grove: Brooks/Cole; 1998;
  9. Law RO. Taurine efflux and the regulation of cell volume in incubated slices of cerebral cortex. Biochim. Biophys. Acta. 1994;1221:21–28
  10. Lefauconnier JM, Urban F, Mandel P. Taurine transport into brain in rat. Biochemie. 1976;60:381–387
  11. Lund E. In: Oxysterols. Studies On Biosynthesis and Regulatory Importance. Stockholm: Karolinska Institutet; 1993;
  12. Lähdesmäki P, Oja SS. On the mechanism of taurine transport at brain cell membranes. J. Neurochem. 1973;20:1411–1417
  13. Mahgoub A, Idle J, Dring L, Lancaster R, Smith R. Polymorphic hydroxylation of debrisoquine in man. Lancet. 1977;ii:584–586
  14. McGale EHF, Pye IF, Stonier C, Hutchinson EC, Aber GM. Studies of the inter-relationship between cerebrospinal fluid and plasma amino acid concentrations in normal individuals. J. Neurochem. 1977;29:291–297
  15. Nordin C, Dahl M-L, Eriksson M, Sjöberg S. Is the cholesterol lowering effect of simvastatin influenced by the CYP2D6 polymorphism?. Lancet. 1997;350:29–30
  16. Nordin C, Eklundh T. Lower CSF taurine levels in male pathological gamblers than in healthy controls. Hum. Psychopharmacol. 1996;11:401–403
  17. Oja SS, Lehtinen L, Lähdesmäki P. Taurine transport rates between plasma and tissues in adult and 7-day-old mice. Q. J. Exp. Physiol. 1976;61:133–143
  18. Okamoto K, Kimura H, Sakai Y. Evidence for taurine as an inhibitory neurotransmitter in cerebellar stellate interneurons: selective antagonism by TAG (6-aminomethyl-3-methyl-4H,1,2,4-benzothiadiazine-1,1-dioxide). Brain Res. 1983;265:163–168
  19. Purdy A, Hahn A, Barnett HJ, Bratty P, Ahmad D, Lloyd KG, et al. Familial fatal Parkinsonism with alveolar hypoventilation and mental depression. Ann. Neurol. 1979;6:523–531
  20. Qureshi GA, Baig SM. Role of neurotransmitter amino acids in multiple sclerosis in exacarbation, remission and chronic progressive course. Biogenic Amines. 1993;10:39–48
  21. Saransaari P, Oja SS. Taurine and neural cell damage. Amino Acids. 2000;19:509–526
  22. Vitarella D, DiRisio DJ, Kimelberg HK, Aschner M. Potassium and taurine release are highly correlated with regulatory volume decrease in neonatal primary rat astrocyte cultures. J. Neurochem. 1994;63:1143–1149

PII: S0924-977X(03)00033-6

doi: 10.1016/S0924-977X(03)00033-6

European Neuropsychopharmacology
Volume 13, Issue 5 , Pages 333-335 , October 2003

Article Tools

* Image Usage & Resolution